VHL GENE INACTIVATION

Clinical trials for VHL GENE INACTIVATION explained in plain language.

Never miss a new study

Get alerted when new VHL GENE INACTIVATION trials appear

Sign up with your email to follow new studies for VHL GENE INACTIVATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Oral drug shows promise in shrinking tumors for rare genetic cancer syndrome

Disease control Ongoing

This study is testing an oral drug called belzutifan for people with von Hippel-Lindau (VHL) disease who have kidney tumors. The goal is to see if continuous daily treatment can shrink these tumors and delay the need for surgery. The study will also monitor how the drug affects o…

Matched conditions: VHL GENE INACTIVATION

Phase: PHASE2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control

Last updated Apr 15, 2026 16:14 UTC

VHL GENE INACTIVATION

Get alerted when new VHL GENE INACTIVATION trials appear

Oral drug shows promise in shrinking tumors for rare genetic cancer syndrome